In this episode of The Oncology Brothers podcast, we delved into the unmet need for treatment options in colorectal cancer, particularly in the metastatic space after the second line. The focus was on the FRESCO2 study, which led to the approval of fruquintinib in the United States. Dr. Arvind Dasari, the study’s lead author, joined us to discuss the study design and findings.
Fruquitinib, an oral VEGF tyrosine kinase inhibitor, showed significant improvements in progression-free survival and overall survival compared to placebo in refractory colorectal cancer patients. The study included patients who had exhausted all available therapies, making it a valuable option in the third-line setting and beyond.
The podcast highlighted the tolerability of fruquitninib, with manageable side effects such as hypertension, rash, and fatigue. The discussion also compared fruquintinib and other treatment options like TAS-102 plus bevacizumab, emphasizing the importance of individualized treatment decisions based on patient preferences and clinical situations.
Overall, the episode provided valuable insights into the role of fruquintinib in refractory colorectal cancer and its potential impact on improving patient outcomes in this challenging disease setting.
